AI tool helps to diagnose and predict severity of lung cancers

AI enhances physicians’ ability to identify extent of prostate cancer with 84% accuracy

Unfold AI is better at identifying cancer margins in the prostate than physicians identifying margins by sight, according to a new study. This AI improves accuracy from 67% to 84%, giving physicians more clarity and treatment planning, allowing them to better recommend therapies tailored to each patient.

July 19, 2024

Vol.50 No.29

Cancer History Project

“If I’m not dying, I better go live.” Christy Erickson’s cancer diagnosis led to life as a motorcyclist and strongman competitor

Christy Erickson was seven years old when her mom lost a three-year battle with breast cancer.

July 12, 2024

Vol.50 No.28

By McKenzie Prillaman

Clinical Roundup

Exscientia builds AWS AI-powered platform to advance drug discovery

Exscientia plc announced it will be expanding its work with Amazon Web Services to use the cloud provider’s artificial intelligence and machine learning services to power its platform for end-to-end drug discovery and automation.

July 12, 2024

Vol.50 No.28

Cancer History Project Guest Editorial

At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.

July 05, 2024

Vol.50 No.27

By Katerina A. Politi and Roy S. Herbst

In the Archives

The early days of EGFR: Herbst, Haber, Meyerson, Pao, Sequist present at Yale SPORE workshop

In 1998, lung cancer was the leading cause of cancer deaths in the United States, with 160,000 deaths per year. That statistic inspired Matthew Meyerson, who would soon start working at the Dana-Farber Cancer Institute, to specialize in lung cancer.

July 05, 2024

Vol.50 No.27

In Brief

Miguel Villalona Calero named deputy director of UC Irvine Chao Family CCC

Miguel Villalona Calero was named deputy director of the University of California, Irvine Chao Family Comprehensive Cancer Center and division chief for hematology/oncology. He will start on July 8.

June 28, 2024

Vol.50 No.26

AI tool helps to diagnose and predict severity of lung cancers

YOU MAY BE INTERESTED IN

AI enhances physicians’ ability to identify extent of prostate cancer with 84% accuracy

“If I’m not dying, I better go live.” Christy Erickson’s cancer diagnosis led to life as a motorcyclist and strongman competitor

Exscientia builds AWS AI-powered platform to advance drug discovery

At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago

The early days of EGFR: Herbst, Haber, Meyerson, Pao, Sequist present at Yale SPORE workshop

Miguel Villalona Calero named deputy director of UC Irvine Chao Family CCC

Renew today!

Subscriber content

Login